Is GlobalFoundries On The Verge Of A Breakout?
GLOBALFOUNDRIES Inc. (NASDAQ:GFS) is as a semiconductor foundry whose chips…
Buy
56
CVS Quote, Financials, Valuation and Earnings
Last price:
$63.75
Seasonality move
:
2.11%
Day range:
$62.66 - $64.09
52-week range:
$43.56 - $72.51
Dividend yield:
4.17%
P/E ratio:
15.21x
P/S ratio:
0.21x
P/B ratio:
1.05x
Volume:
7.4M
Avg. volume:
11.9M
1-year change:
11.05%
Market cap:
$80.6B
Revenue:
$372.8B
EPS (TTM):
$4.19
Analysts' Opinion
-
Consensus RatingCVS Health has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 8 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $79.29, CVS Health has an estimated upside of 24.39% from its current price of $63.74.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $71.00 representing -11.39% downside risk from its current price of $63.74.
Fair Value
-
According to the consensus of 21 analysts, CVS Health has 24.39% upside to fair value with a price target of $79.29 per share.
CVS vs. S&P 500
-
Over the past 5 trading days, CVS Health has overperformed the S&P 500 by 4.94% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
CVS Health does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CVS Health has grown year-over-year revenues for 48 quarters straight. In the most recent quarter CVS Health reported revenues of $94.6B.
Earnings Growth
-
CVS Health has grown year-over-year earnings for 1 quarter straight. In the most recent quarter CVS Health reported earnings per share of $1.41.
Enterprise value:
132.9B
EV / Invested capital:
0.94x
Price / LTM sales:
0.21x
EV / EBIT:
13.01x
EV / Revenue:
0.35x
PEG ratio (5yr expected):
0.07x
EV / Free cash flow:
22.36x
Price / Operating cash flow:
13.53x
Enterprise value / EBITDA:
8.96x
Gross Profit (TTM):
$53.2B
Return On Assets:
2.09%
Net Income Margin (TTM):
1.39%
Return On Equity:
7%
Return On Invested Capital:
3.75%
Operating Margin:
3.57%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $330.9B | $360.9B | $379B | $88.4B | $94.6B | |
| Gross Profit | $54.5B | $53.6B | $53.2B | $12.6B | $14.4B | |
| Operating Income | $16B | $13.1B | $10.9B | $2.3B | $3.4B | |
| EBITDA | $12.2B | $17.2B | $14.8B | $3.4B | $4.6B | |
| Diluted EPS | $3.10 | $5.69 | $4.19 | $0.88 | $1.41 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $55.7B | $61.5B | $68.7B | $67.5B | $73.2B | |
| Total Assets | $229.6B | $232.9B | $239.3B | $249.7B | $255.6B | |
| Current Liabilities | $60.1B | $69.8B | $75.1B | $83.3B | $89B | |
| Total Liabilities | $158.4B | $158.7B | $167.8B | $175.6B | $178.5B | |
| Total Equity | $71.2B | $74.1B | $71.6B | $74.2B | $77.1B | |
| Total Debt | $61.9B | $56.3B | $58.2B | $64.1B | $64.7B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $20.1B | $10.9B | $8.8B | $4.9B | $4.6B | |
| Cash From Investing | -$11.6B | -$14.5B | -$6.3B | -$2.1B | -$762M | |
| Cash From Financing | -$5.1B | -$1.3B | -$2.2B | -$1.2B | -$2.3B | |
| Free Cash Flow | $17.4B | $8.1B | $5.9B | $4.2B | $3.8B | |
CVS
Sector
Market Cap
$80.6B
$34.2M
Price % of 52-Week High
87.91%
43.73%
Dividend Yield
4.17%
0%
Shareholder Yield
3.2%
-0.66%
1-Year Price Total Return
11.05%
-41.71%
Beta (5-Year)
0.598
0.657
Dividend yield:
4.17%
Annualized payout:
$2.66
Payout ratio:
63.88%
Growth streak:
3 years
Technicals
8-day SMA
Buy
Level
$62.73
200-day SMA
Buy
Level
$59.30
Bollinger Bands (100)
Buy
Level
52.97 - 68.73
Chaikin Money Flow
Sell
Level
-38.4M
20-day SMA
Sell
Level
$65.01
Relative Strength Index (RSI14)
Sell
Level
46.14
ADX Line
Sell
Level
17.66
Williams %R
Neutral
Level
-61.935
50-day SMA
Sell
Level
$66.30
MACD (12, 26)
Buy
Level
1.15
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Neutral
Level
14.8M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.0539)
Sell
CA Score
(Annual)
Level (-0.6271)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (0.0728)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 27 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all existing business lines.
Stock Forecast FAQ
In the current month, CVS has received 13 Buy ratings 8 Hold ratings, and 0 Sell ratings. The CVS average analyst price target in the past 3 months is $79.29.
-
Where Will CVS Health Stock Be In 1 Year?
According to analysts, the consensus estimate is that CVS Health share price will rise to $79.29 per share over the next 12 months.
-
What Do Analysts Say About CVS Health?
Analysts are divided on their view about CVS Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CVS Health is a Sell and believe this share price will drop from its current level to $71.00.
-
What Is CVS Health's Price Target?
The price target for CVS Health over the next 1-year time period is forecast to be $79.29 according to 21 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is CVS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CVS Health is a Buy. 13 of 21 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CVS?
You can purchase shares of CVS Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CVS Health shares.
-
What Is The CVS Health Share Price Today?
CVS Health was last trading at $63.75 per share. This represents the most recent stock quote for CVS Health. Yesterday, CVS Health closed at $63.74 per share.
-
How To Buy CVS Health Stock Online?
In order to purchase CVS Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Dick’s Sporting Goods Buying Foot Locker Smart?
Last week, Dick’s Sporting Goods (NYSE:DKS) announced that it would…
Is Ginkgo Bioworks Stock a Good Buy?
Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Alerts
Buy
55
RGC alert for May 21
Regencell Bioscience Holdings [RGC] is up 31.16% over the past day.
Buy
64
AKRO alert for May 21
Akero Therapeutics [AKRO] is up 24.59% over the past day.
Buy
76
AGYS alert for May 21
Agilysys [AGYS] is up 22.13% over the past day.
